Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar;9(2):78-84.
doi: 10.1111/irv.12301. Epub 2015 Jan 4.

Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial

Brenda L Coleman  1 , Shaza A Fadel, Steven J Drews, Todd F Hatchette, Allison J McGeer
Affiliations
Randomized Controlled Trial

Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial

Brenda L Coleman et al. Influenza Other Respir Viruses. 2015 Mar.

Abstract

Background: Healthcare workers may be exposed to people with respiratory viral infections more often than other working adults. Understanding the risk and the effectiveness of different preventive measures is of great importance.

Objectives: To estimate adherence to prophylactic antiviral medication for a full influenza season, to the compare efficacy of antiviral prophylaxis to that of the seasonal influenza vaccine and to identify exposures that increase risk of acute respiratory illnesses (ARI) in healthy adults.

Methods: Participants were randomized 1:2 to receive the 2008-2009 influenza vaccine or daily prophylaxis with 10 mg of zanamivir during the season. Web-based questionnaires collected information on demographics, symptoms, exposures, medication use and side effects.

Results: Sixty-four healthy adults were recruited in November 2008. Three of 40 active participants discontinued zanamivir due to side effects; the remaining 37 took >85% of scheduled doses for a median of 121 days. Symptomatic, laboratory-confirmed influenza was detected in one person randomized to zanamivir (2·5%) and 2/20 (10%) who received the vaccine (P = 0·25). Forty-seven participants reported 109 episodes of ARI. Factors associated with an ARI were exposure to a spouse (OR 7·2), child (OR 2·4) or patient (OR 2·0) with symptoms of an ARI in the previous 7 days.

Conclusions: Breakthrough influenza infection occurred in both vaccinated participants and those receiving antiviral prophylaxis. Most adults were willing and able to comply with season-long prophylaxis. Report of recent exposure to family members and patients with an ARI increased the risk of developing an ARI in healthy adults.

Keywords: Adult; antiviral; influenza; respiratory tract infections.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of participation in clinical trial, November 2008 to June 2009.
Figure 2
Figure 2
Number of participants taking antiviral prophylaxis and the percentage of doses taken per week, January – May 2009.
See this image and copyright information in PMC

References

    1. Passioti M, Maggina P, Megremis S, Papadopoulos NG. The common cold: potential for future prevention or cure. Curr Allergy Asthma Rep. 2014;14:413. Epub 2014/01/15. - PMC - PubMed
    1. Donovan TL, Moore KM, VanDenKerkhof EG. Employee absenteeism based on occupational health visits in an urban tertiary care Canadian hospital. Public Health Nurs. 2008;25:565–575. Epub 2008/10/28. - PubMed
    1. Reyes F, Aziz S, Li Y, et al. Influenza in Canada: 2006–2007 season. Can Commun Dis Rep. 2008;34:1–8. - PubMed
    1. Reyes F, Aziz S, Winchester B, et al. Influenza in Canada: 2007–2008 Season Update. Can Commun Dis Rep. 2008;34:1–9. - PubMed
    1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:36–44. - PubMed

Publication types